2 results
Approved WMOCompleted
To assess safety, tolerability and pharmacokinetics of a single subcutaneous administration of HPV-NIRD1.
Approved WMOPending
Phase 1 - Primary Objective• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-129 in patients with NSCLC, GC/GEJ adenocarcinoma, HNSCC or ESCC, with disease progression after prior therapy for…